Følelses- og symptomfokusert engasjementforsøk for personer med akutt leukemi (EASE)
Emosjon og symptomfokusert engasjement (EASE): En randomisert kontrollert prøveperiode på flere steder av en intervensjon for individer med akutt leukemi
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Harriet Richardson
- Telefonnummer: 613-533-6430
- E-post: hrichardson@ctg.queensu.ca
Studer Kontakt Backup
- Navn: Lois Shepherd
- Telefonnummer: 613-533-6430
- E-post: lshepherd@ctg.queensu.ca
Studiesteder
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Rekruttering
- Regional Health Authority B, Zone 2
-
Ta kontakt med:
- Alfonso Rivera Duarte
- Telefonnummer: 506 648-7109
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Rekruttering
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Ta kontakt med:
- Alejandro Garcia-Horton
-
Kingston, Ontario, Canada, K7L 2V7
- Rekruttering
- Kingston Health Sciences Centre
-
Ta kontakt med:
- Annette Hay
- Telefonnummer: 77094 613 533-6430
-
Ottawa, Ontario, Canada, K1H 8L6
- Rekruttering
- Ottawa Hospital Research Institute
-
Ta kontakt med:
- Pierre Villeneuve
- Telefonnummer: 613
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- University Health Network
-
Ta kontakt med:
- Gary Rodin
- Telefonnummer: 416 946-4504
-
Toronto, Ontario, Canada, M4N 3M5
- Rekruttering
- Odette Cancer Centre
-
Ta kontakt med:
- Lee Mozessohn
- Telefonnummer: 5847 416 480-5000
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Annet: Vanlig pleie
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
Eksperimentell: Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
Tidsramme: 4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Vurder effekten av EASE-intervensjonen sammenlignet med vanlig behandling for å redusere traumatiske stresssymptomer ved å bruke SASRQ
Tidsramme: 8 uker, 12 uker og 26 uker
|
8 uker, 12 uker og 26 uker
|
|
|
Vurder effekten av EASE-intervensjonen til vanlig omsorg for å redusere alvorlighetsgraden av fysiske symptomer ved bruk av MSAS
Tidsramme: 8 uker, 12 uker og 26 uker
|
8 uker, 12 uker og 26 uker
|
|
|
Vurder effekten av EASE-intervensjonen sammenlignet med vanlig behandling på antall deltakere som oppfyller kriteriene i samsvar med en diagnose av ASD og terskel ASD basert på DSM-5-kriterier ved bruk av SASRQ
Tidsramme: 4, 8, 12 og 26 uker
|
4, 8, 12 og 26 uker
|
|
|
Vurder effekten av EASE-intervensjonen sammenlignet med vanlig pleie på antall fysiske symptomer på kreft og den tilhørende symptomrelaterte plagen målt av (MSAS)
Tidsramme: 4, 8, 12 og 26 uker
|
4, 8, 12 og 26 uker
|
|
|
Vurder effekten av EASE-intervensjonen sammenlignet med vanlig behandling på pasienttilfredshet med behandlingen ved å bruke 16-elementet FAMCAR-P16
Tidsramme: 4, 8, 12 og 26 uker
|
4, 8, 12 og 26 uker
|
|
|
10) EQ-5D-5L vil bli brukt til å måle generisk helsestatus slik at den kan brukes til å beregne kvalitetsjusterte leveår (QALY) i en økonomisk evaluering som sammenligner nytten og kostnaden ved EASE-intervensjonen
Tidsramme: 4, 8, 12, 26 og 52 uker
|
4, 8, 12, 26 og 52 uker
|
|
|
For å sammenligne progresjonsfri overlevelse mellom behandlingsarmene
Tidsramme: 1 år
|
1 år
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
Tidsramme: 4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
Tidsramme: 4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: 4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
Tidsramme: 4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
Tidsramme: Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Studiestol: Gary Rodin, Princess Margaret Hospital, Canada
- Studiestol: Camilla Zimmerman, Princess Margaret Hospital, Canada
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- SC26
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .